Nouscom extends Series C round to $82m for cancer vaccine trials


Immuno-oncology company Nouscom has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its pipeline of personalised and off-the-shelf cancer vaccines. An additional $7.6m was added from Italian venture capital firm Angelini Ventures, joining the round which was first announced in November 2023. The oversubscribed round adds to a Series B round that brought in $49m in November 2017. Switzerland-based Nouscom will use the funds to advance and expand its cancer vaccine clinical pipeline, according to a 21 March press release by Angelini.